Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

The Lancet Infectious Diseases

Volumn 9, Issue 3, 2009, Pages 153-161

  Orenstein, Evan W ^a,b   Basu, Sanjay ^a,b   Shah, N Sarita ^a,c   Andrews, Jason R ^a,d   Friedland, Gerald H ^a,b   Moll, Anthony P ^a,e   Gandhi, Neel R ^a,c   Galvani, Alison P ^a,b  

^a Tugela Ferry Care and Research Collaboration   (South Africa)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Philanjalo and Church of Scotland Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BAYES THEOREM; FOLLOW UP; HEALTH PROGRAM; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PUBLIC HEALTH; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DIRECTLY OBSERVED THERAPY; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 60749083864     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70041-6     Document Type: Review

References (57)

1. Wright A., and Zignol M. Anti-tuberculosis drug resistance in the world: fourth global report (2008), WHO, Geneva
2. Nathanson E., Gupta R., Huamani P., et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 8 (2004) 1382-1384
3. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., and Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 167 (2003) 1472-1477
4. Mitnick C., Bayona J., Palacios E., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348 (2003) 119-128
5. Resch S.C., Salomon J.A., Murray M., and Weinstein M.C. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3 (2006) e241
6. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008 (2008), WHO, Geneva
7. Van Deun A., Salim M.A., Das A.P., Bastian I., and Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 8 (2004) 560-567
8. Park S.K., Lee W.C., Lee D.H., Mitnick C.D., Han L., and Seung K.J. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 8 (2004) 361-368
9. Tahaoǧlu K., Törün T., Sevim T., et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345 (2001) 170-174
10. Keshavjee S., Gelmanova I.Y., Farmer P.E., et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372 (2008) 1403-1409
11. Lew W., Pai M., Oxlade O., Martin D., and Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149 (2008) 123-134
12. Caminero J.A. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10 (2006) 829-837
13. Mukherjee J.S., Rich M.L., Socci A.R., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363 (2004) 474-481
14. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
15. Saravia J.C., Appleton S.C., Rich M.L., Sarria M., Bayona J., and Becerra M.C. Retreatment management strategies when first-line tuberculosis therapy fails. Int J Tuberc Lung Dis 9 (2005) 421-429
16. Smith T.C., Spiegelhalter D.J., and Thomas A. Bayesian approaches to random-effects meta-analysis: a comparative study. Stat Med 14 (1995) 2685-2699
17. Gelman A., Carlin J.B., Stern H.S., and Rubin D.B. Bayesian data analysis (2003), CRC Press, Boca Raton, FL
18. Brooks S., and Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graph Stat 7 (1998) 434-455
19. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., and Horsburgh Jr. C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328 (1993) 527-532
20. Burgos M., Gonzalez L.C., Paz E.A., et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 40 (2005) 968-975
21. Olle-Goig J.E., and Sandy R. Outcomes of individualised treatment for multidrug-resistant tuberculosis before DOTS-plus. Int J Tuberc Lung Dis 9 (2005) 765-770
22. Geerligs W.A., Van Altena R., De Lange W.C.M., Van Soolingen D., and Van Der Werf T.S. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 4 (2000) 758-764
23. Kim H.J., Hong Y.P., Kim S.J., Lew W.J., and Lee E.G. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. Int J Tuberc Lung Dis 5 (2001) 1129-1136
24. Yew W.W., Chan C.K., Chau C.H., et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117 (2000) 744-751
25. Chiang C.Y., Enarson D.A., Yu M.C., et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 28 (2006) 980-985
26. Munsiff S.S., Ahuja S.D., Li J., and Driver C.R. Public-private collaboration for multidrug-resistant tuberculosis control in New York City. Int J Tuberc Lung Dis 10 (2006) 639-648
27. Narita M., Alonso P., Lauzardo M., Hollender E.S., Pitchenik A.E., and Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 120 (2001) 343-348
28. Kwon Y.S., Kim Y.H., Suh G.Y., et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 47 (2008) 496-502
29. Palmero D.J., Ambroggi M., Brea A., et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 8 (2004) 778-784
30. Kim H.R., Hwang S.S., Kim H.J., et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45 (2007) 1290-1295
31. Uffredi M.L., Truffot-Pernot C., Dautzenberg B., Renard M., Jarlier V., and Robert J. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 29 (2007) 434-439
32. Nathanson E., Lambregts-van Weezenbeek C., Rich M.L., et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 12 (2006) 1389-1397
33. Mitnick C.D., Shin S.S., Seung K.J., et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 359 (2008) 563-574
34. Tupasi T.E., Quelapio M.I., Orillaza R.B., et al. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed. Tuberculosis (Edinb) 83 (2003) 52-58
35. Holtz T.H., Sternberg M., Kammerer S., et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 144 (2006) 650-659
36. Leimane V., Riekstina V., Holtz T.H., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365 (2005) 318-326
37. Mirsaeidi S.M., Tabarsi P., Khoshnood K., et al. Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. Int J Infect Dis 9 (2005) 317-322
38. Shin S.S., Pasechnikov A.D., Gelmanova I.Y., et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 11 (2007) 1314-1320
39. Kim D.H., Kim H.J., Park S.K., et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 178 (2008) 1075-1082
40. Bartu V. Multidrug-resistant tuberculosis in the Czech Republic: strategy and therapeutic outcomes. Eur J Clin Microbiol Infect Dis 26 (2007) 603-605
41. Riekstina V., Leimane V., Holtz T.H., Leimans J., and Wells C.D. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis 11 (2007) 585-587
42. Cox H.S., Kalon S., Allamuratova S., et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS ONE 2 (2007) e1126
43. Eker B., Ortmann J., Migliori G.B., et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 14 (2008) 1700-1706
44. Suárez P.G., Floyd K., Portocarrero J., et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet 359 (2002) 1980-1989
45. Masjedi M.R., Tabarsi P., Chitsaz E., et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 12 (2008) 750-755
46. Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149 (1994) 1359-1374
47. Farmer P., Kim J.Y., Mitnick C.D., and Becerra M. Protocol for the implementation of individualized treatment regimens for multidrug-resistant tuberculosis in resource-poor settings. In: Espinal M.A. (Ed). Multidrug resistant tuberculosis (MDR TB): basis for the development of an evidence-based case-management strategy for MDR TB within the World Health Organization's DOTS strategy (1999), WHO, Geneva
48. Laserson K.F., Thorpe L.E., Leimane V., et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 9 (2005) 640-645
49. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis (2006), WHO, Geneva
50. Chang K.C., Leung C.C., Yew W.W., Ho S.C., and Tam C.M. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 170 (2004) 1124-1130
51. Frieden T.R., and Sbarbaro J.A. Promoting adherence to treatment for tuberculosis: the importance of direct observation. Bull World Health Organ 85 (2007) 407-409
52. Volmink J., and Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 4 (2007) CD003343.
53. Obermeyer Z., Abbott-Klafter J., and Murray C.J. Has the DOTS strategy improved case finding or treatment success? An empirical assessment. PLoS ONE 3 (2008) e1721
54. Wells C.D., Cegielski J.P., Nelson L.J., et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 suppl 1 (2007) S86-S107
55. Gandhi N.R., Moll A., Sturm A.W., et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 (2006) 1575-1580
56. Katiyar S.K., Bihari S., Prakash S., Mamtani M., and Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 12 (2008) 139-145
57. WHO. The Stop TB strategy: building on and enhancing DOTS to meet the TB-related Millenium Development Goals (2006), WHO, Geneva